新兴的免疫疗法治疗疾病改变的1型糖尿病
Timothy P Foster1, Brittany S Bruggeman2, Michael J Haller2,3
1Division of Endocrinology, Department of Pediatrics, College of Medicine, University of Florida, 1699 SW 16th Ave, Building A, Gainesville, FL, 32608, USA. tpfoster@ufl.edu.
Drugs
|January 28, 2025
概括
免疫疗法在1型糖尿病 (T1DM) 方面表现有前途,因为它可以保持胰岛素的产生. 最近的批准和正在进行的试验旨在预防或逆转T1DM,改变未来的护理.
科学领域:
- 免疫学 免疫学 免疫学
- 内分泌学 在内分泌学.
- 糖尿病研究 糖尿病研究
背景情况:
- 1型糖尿病 (T1DM) 涉及自身免疫性破坏胰岛素生成β细胞.
- 目前的T1DM治疗侧重于激素替代和葡萄糖监测.
- 免疫疗法为维护β细胞功能提供了一个新的途径.
研究的目的:
- 审查40年来针对T1DM的免疫疗法试验.
- 评估T1DM免疫疗法研究中的成功和失败.
- 概述T1DM免疫疗法的未来方向.
主要方法:
- 对T1DM的历史免疫疗法试验的分析.
- 评估FDA批准的T1DM免疫疗法.
- 审查正在进行的临床试验,重新利用自身免疫性疾病疗法.
主要成果:
- 德普利祖马布的批准标志着延迟临床T1DM发病的里程碑.
- 许多免疫调节疗法已经在40多年里被探索.
- 临床试验继续研究新型和重新定位的免疫疗法.
结论:
- 免疫疗法具有改变T1DM管理的巨大潜力.
- 保持内源性胰岛素的生产是关键的治疗目标.
- 该领域正在通过基于免疫的策略向变革性的T1DM护理迈进.
相关概念视频
Diabetes Mellitus: Overview and Type I Subtype
2.4K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.4K
Diabetes: Management and Pharmacotherapy
233
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
233
Diabetes Mellitus: Type 2 and Gestational
2.2K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.2K
Tumor Immunotherapy
466
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
466
Insulin: Dosing Regimen and Adverse Effects
141
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
141
Glucagon-like Receptor Agonists
294
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
294


